ASI 2017*
Chair: Mark Smyth
Targeting the immune system in osteosarcoma (49400)
3:00 PM
CESTEM-1 clinical trials: using dynamin inhibitors to reverse resistance to monoclonal antibody therapy. (49404)
3:20 PM
IL-15 dependent melanoma-resident CD8+ T cell numbers predict patient survival and outcome of anti-PD1 therapy - Mainthan Palendira
Therapeutic implication of Programmed cell death-1 ligand 2 (PD-L2) against Melanoma - Rebecca Faleiro